Literature DB >> 16246864

Protein composition of the intranuclear inclusions of FXTAS.

C K Iwahashi1, D H Yasui, H-J An, C M Greco, F Tassone, K Nannen, B Babineau, C B Lebrilla, R J Hagerman, P J Hagerman.   

Abstract

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder caused by premutation expansions (55-200 CGG repeats) in the fragile X mental retardation 1 (FMR1) gene. The pathologic hallmark of FXTAS is the ubiquitin-positive intranuclear inclusion found in neurons and astrocytes in broad distribution throughout the brain. The pathogenesis of FXTAS is likely to involve an RNA toxic gain-of-function mechanism, and the FMR1 mRNA has recently been identified within the inclusions. However, little is known about the proteins that mediate the abnormal cellular response to the expanded CGG repeat allele. As one approach to identify the protein mediators, we have endeavoured to define the protein complement of the inclusion itself. Fluorescence-activated flow-based methods have been developed for the efficient purification of inclusions from the post-mortem brain tissue of FXTAS patients. Mass spectrometric analysis of the entire protein complement of the isolated inclusions, combined with immunohistochemical analysis of both isolated nuclei and tissue sections, has been used to identify inclusion-associated proteins. More than 20 inclusion-associated proteins have been identified on the basis of combined immunohistochemical and mass spectrometric analysis, including a number of neurofilaments and lamin A/C. There is no dominant protein species in the inclusions, and ubiquitinated proteins represent only a minor component; thus, inclusion formation is not likely to reflect a breakdown in proteasomal degradation of nuclear proteins. The list of proteins includes at least two RNA binding proteins, heterogeneous nuclear ribonucleoprotein A2 and muscle blind-like protein 1, which are possible mediators of the RNA gain-of-function in FXTAS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16246864     DOI: 10.1093/brain/awh650

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  169 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity.

Authors:  Gloria V Echeverria; Thomas A Cooper
Journal:  Brain Res       Date:  2012-02-22       Impact factor: 3.252

Review 3.  RNA-mediated neurodegeneration in repeat expansion disorders.

Authors:  Peter K Todd; Henry L Paulson
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

Review 4.  Role of noncoding RNAs in trinucleotide repeat neurodegenerative disorders.

Authors:  Huiping Tan; Zihui Xu; Peng Jin
Journal:  Exp Neurol       Date:  2012-01-27       Impact factor: 5.330

Review 5.  Taking STEPs forward to understand fragile X syndrome.

Authors:  Susan M Goebel-Goody; Paul J Lombroso
Journal:  Results Probl Cell Differ       Date:  2012

Review 6.  General Anesthetic Use in Fragile X Spectrum Disorders.

Authors:  Andrew Ligsay; Marwa El-Deeb; Maria J Salcedo-Arellano; Nina Schloemerkemper; Jeremy S Grayson; Randi Hagerman
Journal:  J Neurosurg Anesthesiol       Date:  2019-07       Impact factor: 3.956

Review 7.  FMR1: a gene with three faces.

Authors:  Ben A Oostra; Rob Willemsen
Journal:  Biochim Biophys Acta       Date:  2009-02-21

8.  Two FMR1 premutation cases without nuclear inclusions.

Authors:  Verónica Martínez-Cerdeño; Mirna Lechpammer; Paul J Hagerman; Randi Hagerman
Journal:  Mov Disord       Date:  2017-06-01       Impact factor: 10.338

Review 9.  Pathogenic mechanisms of myotonic dystrophy.

Authors:  Johanna E Lee; Thomas A Cooper
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

Review 10.  Fragile X: a family of disorders.

Authors:  Weerasak Chonchaiya; Andrea Schneider; Randi J Hagerman
Journal:  Adv Pediatr       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.